2019’s Top Biopharma Deal-Makers
Executive Summary
Gene therapy and targeted oncology treatments dominated the biggest acquisitions of the year. Boehringer Ingelheim and Roche were the most active big pharma in-licensers. Cancer and neurology were the focus of most alliances and financings.